Research published in the journal Radiology shows that the combination of transparency-based lesion detection, volumetric density and quantitative texture analysis enables improved prediction of breast cancer risk
ScreenPoint Medical announced the acquisition of Biomediq A/S, a research-based company focused on the discovery, development and implementation of quantitative imaging biomarkers. After a decade of working closely together as separate entities in image-based risk assessment, this deal is designed to bring breast cancer risk assessment capabilities to ScreenPoint’s industry-leading breast AI, Transpara.
Biomediq’s breast cancer risk analysis technology enables automated, computer-assisted interpretation of 2D and 3D mammograms to analyze future breast cancer risk. It is based on a mammographic texture risk biomarker that detects tissue heterogeneity, often referred to as mammographic texture, which is associated with both short- and long-term breast cancer risk.
The potential of Transpara’s detection and density tools combined with Biomediq’s texture model was highlighted in a 2023 publication, “Assessing Breast Cancer Risk by Combining AI for Lesion Detection and Mammographic Texture .” In this Radiology publication, Lauritzen et al. showed that the combination of Transpara-based lesion detection, volumetric density measurement, and quantitative texture analysis leads to improved risk prediction. In addition, further imaging for women at highest Transpara risk could have doubled early cancer detection by detecting interval cancer before subsequent visits compared to traditional screening. The first author of this work, Dr. Andreas D. Lauritzen , will join the ScreenPoint team to accelerate the development of Transpara’s risk capabilities.
Also Read: FIRE1 Raises $120M to Transform Heart Failure Care
Transpara is the most clinically validated breast AI on the market, providing radiologists with a “second pair of eyes ” to detect cancers earlier and reduce recall rates. ScreenPoint recently launched Transpara 2.1, an updated algorithm based on additional training and insights gathered from notable users around the world. Transpara 2.1 is compatible with automatic breast density options (BIRADS and volumetric) and a robust temporal comparison option. The unmatched temporal comparison capability, where suspicious areas from a current study can be analyzed against up to three previous studies over a six-year period, is the first of its kind on the market. Transpara Detection (2.1) and the Temporal Comparison and Density options are CE marked and FDA cleared.
“Risk-stratified screening has long been proposed to optimize patient care and make better use of resources,” said Professor Nico Karssemeijer , co-founder and Chief Scientific Officer of ScreenPoint Medical. “We are excited to add Biomediq’s risk analysis technology to extend Transpara’s capabilities and improve performance in mammography-based breast cancer risk assessment. This is a critical step towards accurate and consistent breast cancer detection and treatment for all women.
According to Biomediq co-founder Professor Mads Nielsen , “Our long-standing collaboration and close relationship with the ScreenPoint team is based on our shared vision to enable better screening for women. Bringing together our technologies to support workflows in radiology and women’s care is an exciting result of this intensive and complementary collaboration.” Prof. Nielsen will continue to advise the expanded ScreenPoint team.
With more than 35 peer-reviewed publications, Transpara is the only breast AI algorithm that has been evaluated multiple times in large, real-world screening populations (including UCLA , Capital Region of Denmark , Lund University in Sweden, Norwegian Cancer Registry, Reina Sofia Hospital Cordoba). The study shows that Transpara can detect up to 45% of interval cancers earlier, while reducing workload and optimizing workflow.
Source: PRNewswire